Spurious Drugs Alert: Diazepam, PAN 40, and PAN-D Capsules Under Investigation
- byDoctor News Daily Team
- 22 September, 2025
- 0 Comments
- 0 Mins
New Delhi: The Central Drugs Standard Control Organisation (CDSCO) has raised alarms over three batches of critical medicines, including anti-anxiety and gastrointestinal drugs, after they were found potentially spurious or non-compliant with prescribed standards. The batches under scrutiny are Diazepam Injection I.P. (Batch No. DA-2403), Pantoprazole Gastro-resistant Tablets PAN 40 (Batch No. 24440993), and Pantoprazole Gastro-resistant and Domperidone Prolonged-Release Capsules PAN-D (Batch No. 23443507). These drugs, commonly used in hospitals and for outpatient treatment, were tested in CDSCO laboratories in Bihar in August 2025. According to official reports, the products are under investigation. The manufacturers for these batches are currently under investigation. In accordance with the Drug and Cosmetic Act, a drug shall be deemed to be spurious— (a) if it is imported under a name which belongs to another drug; or (b) if it is an imitation of, or a substitute for, another drug or resembles another drug in a manner likely to deceive or bears upon it or upon its label or container the name of another drug unless it is plainly and conspicuously marked so as to reveal its true character and its lack of identity with such other drug; or (c) if the label or the container bears the name of an individual or company purporting to be the manufacturer of the drug, which individual or company is fictitious or does not exist; or (d) if it has been substituted wholly or in part by another drug or substance; or (e) if it purports to be the product of a manufacturer of whom it is not truly a product The term “Spurious Drug” has been defined under Section 17-B of the Drugs and Cosmetics Act, 1940 Medicines Flagged as Spurious Name of Product Manufacturing Dates Manufacturer Details Reporting Source Reporting by Lab/State Reporting Month & Year Diazepam Injection I.P. ml Manufacturing Date: Mar-2024Expiry Date: Feb-2026 Manufacturer Name: Under Investigation Manufactured By: Under Investigation Drugs Inspector, Bihar NSQ Remark: N/AFirm Reply: N/A Pantoprazole Gastro-resistant Tablets IP (PAN 40) Manufacturing Date: Mar-2024Expiry Date: Aug-2026 Manufacturer Name: Under Investigation Manufactured By: Under Investigation Drugs Inspector, Bihar NSQ Remark: N/AFirm Reply: N/A Pantoprazole Gastro-resistant and Domperidone Prolonged-Release Capsules IP (PAN-D) Manufacturing Date: Sep-2023 Expiry Date: Aug-2025 Manufacturer Name: Under Investigation Manufactured By: Under Investigation Drugs Inspector, Bihar NSQ Remark: N/AFirm Reply: N/A
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
Recent News
NEET counselling: Maha CET Cell notifies revised r...
- 26 October, 2025
AYUSH Ministry, ICMR to host national seminar on l...
- 26 October, 2025
Dermatologists urge Maha Medical Council to crackd...
- 26 October, 2025
Illegal sex determination racket busted in Mysuru,...
- 26 October, 2025
Daily Newsletter
Get all the top stories from Blogs to keep track.
0 Comments
Post a comment
No comments yet. Be the first to comment!